Supplements
Co-Packer vs In-House Manufacturing: The Margin Trade for Supplement Brands (2026)
A supplement brand should stay with a co-packer until annual volume clears roughly 275,000 bottles per SKU family. Below that, fixed cGMP overhead and capex amortization make in-house cost per unit higher than the contract price. Above it, the margin gain finally beats the fixed-cost and volume-risk burden.
Key Takeaways
- In-house production beats co-packer cost per unit only above roughly 275,000 bottles per year in our base model, where in-house lands near $4.12 vs the co-packer's $4.20.
- A modest in-house cGMP line carries about $636,000 a year in fixed cost: roughly $286,000 capex amortization plus $350,000 in QA and compliance overhead.
- Co-packer per-unit pricing runs about $3.90 to $5.00 per finished bottle in 2026, and barely falls with volume because the co-packer keeps the scale benefit.
- Bringing production in-house converts variable cost into fixed cost, which raises your breakeven and your risk if demand softens.
- With the prime rate at 6.75% in June 2026, financing a $2M buildout adds real interest drag that the margin gain has to clear first.
Every supplement founder who hits a few million in revenue gets the same idea: "If I owned the factory, I would keep the margin my co-packer is taking." It is a reasonable instinct. Your contract manufacturer is charging you $4 to $5 a bottle and you can see the raw materials cost a fraction of that. The gap looks like free money.
It is not free. Moving in-house trades a variable cost you only pay when you sell for a fixed cost you pay whether you sell or not. That trade can be brilliant or it can sink you, and the deciding factor is almost entirely volume. This post gives you the breakeven framework so you can run the math before you sign a facility lease. It is one of the bigger capital calls a brand makes, and the kind of decision our fractional CFO for supplements brands work exists to pressure-test.
The trade you are actually making
A co-packer charges a per-unit price. Sell 10,000 bottles, you pay for 10,000 bottles. Sell zero, you pay for zero. That is the beauty of contract manufacturing: it is pure variable cost, and it flexes with demand. The price you pay includes their margin, their cGMP compliance, their equipment, and their overhead, all bundled into one number.
In-house flips the cost structure. You spend capex up front, you carry fixed cGMP and QA overhead every month, and your per-bottle variable cost drops to roughly the raw materials, direct labor, and packaging. The variable cost is lower. The problem is the fixed cost sits there every month regardless of what you sell. You have converted a flexible cost into a commitment.
That is the margin trade in one sentence: you lower your variable cost per unit in exchange for taking on fixed cost and volume risk. Whether it pays depends on how many units you can spread that fixed cost across. For more on why this distinction drives EBITDA, taxes, and cash flow, see our primer on what is capex vs opex.
The numbers behind the decision
Here is the base model. These are planning figures, not a quote, and you should rebuild them with your own data.
Co-packer side: finished bottle pricing in 2026 runs about $3.90 to $5.00 per unit all-in for a 60-count capsule SKU, per supplement contract manufacturer cost guides. Critically, this barely falls as you scale, because the co-packer captures most of the volume benefit. Custom-formula MOQs typically sit at 2,500 to 5,000 units per SKU.
In-house side: a modest cGMP line costs roughly $2.0M to build (facility buildout, encapsulation line, lab and QA equipment). Amortized over seven years that is about $286,000 a year. Fixed cGMP, QA, and compliance overhead adds about $350,000 a year, consistent with industry estimates of $150,000 to $500,000 for a small-to-mid operation. That is roughly $636,000 in annual fixed cost before you make a single bottle. Your variable cost in-house is about $2.00 per bottle.
The formula is simple:
In-house cost per bottle = $2.00 + ($636,000 / annual volume)
| Annual volume | Co-packer per bottle | In-house per bottle | Lower cost |
|---|---|---|---|
| 50,000 | $4.80 | $14.72 | Co-packer |
| 100,000 | $4.50 | $8.36 | Co-packer |
| 200,000 | $4.30 | $5.18 | Co-packer |
| 250,000 | $4.30 | $4.54 | Co-packer |
| 300,000 | $4.20 | $4.12 | In-house |
| 600,000 | $4.00 | $3.06 | In-house |
| 1,000,000 | $3.90 | $2.64 | In-house |
Where the lines cross
The crossover sits at roughly 275,000 bottles per year. Below it, your fixed cost is spread too thin and in-house is more expensive per unit than just paying the co-packer. Above it, the fixed cost finally dilutes and the lower variable cost wins.
Notice the shape. The co-packer line is nearly flat: a small brand and a large brand pay almost the same per unit. The in-house line is a cliff that drops fast as volume rises. At a million units the gap is about $1.26 per bottle in your favor, which is real money. At 100,000 units, going in-house would nearly double your per-unit cost. Same decision, opposite outcome, driven entirely by volume.
This is consistent with what public companies show. Asset-light CPG brands run capex below 2% of revenue, while manufacturing-heavy food and beverage CPG runs 2.7% to 10.8%, per our capex intensity by DTC vertical analysis. Owning production moves you decisively into the asset-heavy camp.
The costs the spreadsheet hides
The per-unit math is the easy part. Three things quietly raise your real breakeven.
Volume risk. Once your cost is fixed, a soft quarter hurts twice: you lose the revenue and you still pay the $636,000. With a co-packer, a soft quarter just means a smaller order. In-house raises your operating leverage in both directions.
The cGMP burden. Owning a 21 CFR Part 111 facility means you own the audits, the batch records, the supplier qualification, the calibration, and the QA staffing. Your co-packer absorbs that today inside their per-unit price. In-house, it becomes your headache and your headcount.
The cost of capital. With the U.S. prime rate at 6.75% as of June 2026 (FRED, DPRIME), financing a $2M buildout is not cheap. Interest is a real annual drag that your margin gain has to clear before the move actually creates value. The same per-unit gain is worth far less if you borrowed at 9% to get it.
These costs also reshape your landed cost and your pricing floor. If you are still setting prices off your supplier invoice rather than fully-loaded cost, fix that first using our guides to what is landed cost and how to price supplements.
What to do about it
- Pull your real trailing-twelve-month unit volume by SKU family. Not revenue, units. This is the single most important input.
- Get a current all-in co-packer quote per finished bottle at your actual order size, including packaging.
- Build the in-house side honestly: capex amortized over its useful life, fixed cGMP and QA overhead, and true variable cost per bottle. Do not lowball the overhead.
- Find your crossover: fixed cost divided by (co-packer price minus in-house variable cost). In our base model that is $636,000 / ($4.30 - $2.00), about 277,000 units.
- Apply a demand haircut. Run the breakeven at 70% of your forecast. If in-house still wins at the haircut, the decision is durable. If it only wins at full forecast, you are betting the factory on hitting plan.
- Add financing cost. Layer in the interest on whatever you borrow at today's 6.75% prime and confirm the margin gain still clears it.
- If you are close to the line, negotiate first. A co-packer will often cut per-unit price for a volume commitment, which can beat owning the line with none of the risk. See our breakdown of the cGMP cost in COGS.
Methodology
The model assumes a 60-count capsule SKU with a co-packer all-in finished price of $3.90 to $5.00 per bottle in 2026, sourced from current supplement contract manufacturer cost guides and cross-checked against industry MOQ norms of 2,500 to 5,000 units per custom SKU. In-house assumes $2.0M capex amortized straight-line over seven years (about $286,000 a year), $350,000 in annual fixed cGMP and QA overhead (inside the $150,000 to $500,000 industry range reported by SupplySide Supplement Journal), and $2.00 per bottle variable cost. The prime rate of 6.75% is the June 2026 value from FRED series DPRIME. Capex intensity context comes from Eightx public 10-K analysis. These are illustrative planning figures; rebuild them with your own quotes and volume before deciding.
Frequently Asked Questions
when should a supplement brand move from a co-packer to in-house manufacturing?
When sustained annual volume clears roughly 275,000 bottles per SKU family and you have proven, stable demand. Below that, fixed cGMP overhead and capex amortization make in-house cost per unit higher than the co-packer price.
how much does it cost to build an in-house supplement manufacturing facility?
A modest 21 CFR Part 111 cGMP operation runs roughly $1.5M to $5M in startup capex: facility buildout, an encapsulation or tablet line, and lab and QA equipment. Annual compliance overhead typically adds $150,000 to $500,000.
what does a supplement co-packer charge per unit?
In 2026, finished bottle pricing commonly runs about $3.90 to $5.00 per unit all-in, with small or pilot runs higher. Custom-formula MOQs are usually 2,500 to 5,000 units per SKU.
how much gross margin do you gain by manufacturing supplements in-house?
At high volume our model shows in-house cost per bottle dropping to roughly $2.64 vs a co-packer's $3.90, a gain of about $1.26 per unit. But that gain only materializes after fixed cost is spread across very large volume.
what is the biggest risk of bringing supplement production in-house?
Volume risk. In-house converts variable cost into fixed cost, so if demand softens you still carry the full capex amortization, cGMP overhead, and idle-capacity cost. That raises your breakeven and your downside.
does the cost of borrowing affect the in-house manufacturing decision?
Yes. With the prime rate at 6.75% in June 2026, financing a $2M buildout adds meaningful annual interest. The margin gain from owning production has to clear that financing cost before the move pays off.